Diocese of Hyderabad

Social Awareness Program

Corona Virus Disease

2019
by Dr. Khurram Shahzad
(MBBS)
• It is medically classified as an ss-RNA virus
• It is surrounded by an envelop. Introduction
• It has a size of 100 nm
• 2 human serotypes have been discovered. ss-RNA Virus
• Can cause Common Cold to severe diseases
like SARS & MERS

Contoso
Pharmaceuticals

page 2
History

Contoso
Pharmaceuticals

page 3
Transmission & Epidemiology
• Corona Virus can cause Zoonotic infections;
• “This virus is closely related to known bat viruses. That’s why it’s believed to have originated from a bat,
they can infect multiple mammals and cross between species” Dr. Jeff Kwong
• The first case of SARS-COVID-19 was reposted on Nov 17th, 2019. By the end of 2019 China alone
reported over 80,000 cases. Why?
• “It’s been in China for a number of months already. It’s not the most contagious spread of infection —
there’s a lot of other diseases that are much more contagious — but because there’s a lack of immunity in
the population, we’re seeing a widespread transmission,” Kwong said;
• Transmitted by Respiratory Aerosol;

Contoso
Pharmaceuticals

page 4
Pathogenesis
• Approximately 50% of infections are asymptomatic
• Immunity following infection appears to be brief, and reinfection can occur.
• Pneumonia caused by SARS coronavirus is characterized by diffuse edema resulting in hypoxia.

Contoso
Pharmaceuticals

page 5
Risk Factors
• Age
• Comorbidities
• Low Immunity
• Exposure to certain mammals

Contoso
Pharmaceuticals

page 6
Clinical Findings
• Common Cold: coryza, scratchy sore throat, and low-grade fever.
• SARS: severe atypical pneumonia characterized by a fever of at least 38°C, nonproductive cough,
dyspnea, and hypoxia. Chills, rigors, malaise, and headache commonly occur, but sore throat and
rhinorrhea are uncommon.

Contoso
Pharmaceuticals

page 7
Timeline

Experience fatigue
Myalgia
Runs Fever Worsening of
Dry cough symptoms
Mild Sore Throat

Day Day Day Day Day Day Day Day Day

1 2 3 4 5 6 7 8 9

Sore Throat
Hoarse Voice Mild Fever High grade fever
Body Temp increase Cough Cough with
pronounced sputum
Anorexia begins Dyspnea
Headache Diarrhea or vomiting
Myalgia Contoso
Pharmaceuticals
Diarrhea or vomiting
Diarrhea
page 8
Laboratory Diagnosis
• Common cold: Clinical
• SARS or MERS:
CBC: Deranged WBC
Antibody-based and PCR-based tests can be used.

Contoso
Pharmaceuticals

page 9
Prevention
• Screening: before pt. even enters into health care facility
• The WHO recommends standard, contact, and droplet precautions (i.e. gloves and mask) with eye or
face protection
• Self-isolation for 14 days in case they develop symptoms and to prevent spreading the virus to others;
• Community based measures to reduce transmission:
●Diligent hand washing, use of hand sanitizer that contains at least 60% alcohol
●Respiratory hygiene (e.g., covering the cough or sneeze).
●Avoiding touching the face (in particular eyes, nose, and mouth).
●Avoiding crowds if possible and avoiding close contact with ill individuals.
●Cleaning and disinfecting objects and surfaces that are frequently touched.

Contoso
Pharmaceuticals

page 10
Prevention

Contoso
Pharmaceuticals

page 11
Prevention

Contoso
Pharmaceuticals

page 12
Precautions

Contoso
Pharmaceuticals

page 13
Management
• Suspicion – cough & dyspnea
• Isolation – Home Care to prevent transmission and monitor clinical deterioration. 2 strategies can be
employed during Home Care;
• When a test-based strategy is used, patients may discontinue home isolation when there is:
•Resolution of fever without the use of fever-reducing medications AND
•Improvement in respiratory symptoms (eg, cough, shortness of breath) AND
•Negative results of at least two consecutive nasopharyngeal swabs collected ≥24 hours apart
• When a non-test-based strategy is used, patients may discontinue home isolation when the following
criteria are met:
•At least seven days have passed since symptoms first appeared AND
•At least three days (72 hours) have passed since recovery of symptoms (defined as resolution of fever
without the use of fever-reducing medications and improvement in respiratory symptoms [eg, cough,
shortness of breath])

Contoso
Pharmaceuticals

page 14
Specimen Collection

If Positive If Negative If still Negative

1. If positive, repeat every 1. If negative, repeat once • If negative for 2

3 days till negative after 24 hrs consecutive times,
Isolation can be
discontinued. But do
practice precautions

Contoso
Pharmaceuticals

page 15
Contoso
Pharmaceuticals

page 16
Why Italy?
• Mean age if 64 years.
• Lack of Immunity
• Possibly due to use of Ibuprofen

Contoso
Pharmaceuticals

page 17
 Summary
Summary tagline or
sub-headline

Contoso
Pharmaceuticals

page 18
 Could it get worse?
“I think we’re going to see many more cases
in the coming months and even years,”
- Dr. Kwong.
Contoso
Pharmaceuticals

page 19
The Problem

Declining Market Financial Trust Cost Margins

Lorem ipsum dolor sit Etiam aliquet eu mi Integer convallis Suspendisse sit amet Ut congue quis tortor
amet, consectetur quis lacinia. Ut suscipit ante eu ipsum varius finibus varius eget sodales.
adipiscing elit. fermentum a magna varius. Morbi a purus justo viverra blandit.
ut eleifend. dolor.

Contoso
Pharmaceuticals

page 20
 Prioritize Authorize Monetize Solution
Lorem ipsum dolor sit Etiam aliquet eu mi Integer convallis
amet, consectetur
adipiscing elit.
quis lacinia. suscipit ante eu
varius.
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Etiam aliquet eu mi quis.
Contoso
Pharmaceuticals

page 21
 Unique First to Market
Lorem ipsum dolor sit Etiam aliquet eu mi.
amet, consectetur Ut fermentum a
adipiscing elit. magna ut eleifend.

Product
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Tested Authentic Etiam aliquet eu mi quis.
Integer convallis Suspendisse sit amet
suscipit eu varius.
Morbi a purus dolor.
ipsum varius finibus
justo viverra blandit.
Contoso
Pharmaceuticals

page 22
Emphasize your
main benefit
Other benefits include
• Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
• Nunc tempus, risus sodales hendrerit,
arcu dolor commodo libero. Contoso
Pharmaceuticals

page 23
Business Model
Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Research Finance Invest

Lorem ipsum dolor sit Etiam aliquet eu mi Integer convallis
amet, consectetur quis lacinia. Ut suscipit ante eu
adipiscing elit. fermentum a magna varius. Morbi a purus
ut eleifend. dolor.

Contoso
Pharmaceuticals

page 24
Market Opportunity Option 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit.

$1B
• Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
• Etiam aliquet eu mi quis
lacinia. Ut fermentum a
magna ut eleifend. Integer
convallis suscipit ante eu
varius.
• Morbi a purus dolor.
Suspendisse sit amet ipsum
finibus justo viverra blandit.
$2B
• Ut congue quis tortor eget
sodales. Nulla a erat eget
nunc hendrerit ultrices eu nec
nulla.
• Donec viverra leo aliquet,
auctor quam id, convallis orci.
Contoso
Pharmaceuticals

page 25
Market Opportunity Option 2
Integer convallis suscipit ante eu varius. Morbi a purus dolor.

$3B
Opportunity to Build
$2B
Freedom to Invent
$1B
Few Competitors

Lorem ipsum dolor sit Etiam aliquet eu mi quis Integer convallis suscipit
amet, consectetur lacinia. Ut fermentum a ante eu varius. Morbi a
adipiscing elit. magna ut eleifend. purus dolor.

Contoso
Pharmaceuticals

page 26
Competition Option 1

Contoso Pharmaceuticals Competitor

• Nulla a erat eget nunc hendrerit ultrices eu nec
nulla. Donec viverra leo aliquet, auctor quam id,
convallis orci.
• Sed in molestie est. Cras ornare turpis at ligula
posuere, sit amet accumsan neque lobortis.
• Maecenas mattis risus ligula, sed ullamcorper nunc
efficitur sed.
• Praesent venenatis quam tortor, id viverra nunc
rutrum a.
• Maecenas malesuada ultricies sapien sit amet
pharetra.
• Nunc tempus, risus sodales hendrerit, arcu dolor
commodo libero, a sollicitudin quam nulla quis
lectus. In at porta mauris.

Contoso
Pharmaceuticals

page 27
Competition Option 2
Convenience

Contoso
Pharmaceuticals

Expensive Affordable

Inconvenient Contoso
Pharmaceuticals

page 28
Traction
Forecasting for success

Vendors Users Gross Company

Revenue Revenue Gross Revenue
$300,000

20YY 0 0 $0 $0
$250,000

20YY 10 100 $6,750 $1,013 $200,000

$150,000
20YY 50 500 $33,750 $5,063

$100,000
20YY 200 2000 $135,000 $20,250
$50,000

20YY 400 4000 $270,000 $40,500 $0

1 2 3 4 5 Contoso
Pharmaceuticals

page 29
Financials
Year 1 Year 2 Year 3
Detailers 5,000 40,000 160,000
Users 50,000 400,000 1 600,000
Sales 500,000 4 000,000 16 000,000
Average Price per Sale 75 80 90
Revenue @ 15% 5 625,000 48 000,000 216 000,000
• Cost of Revenue 0 0 0
Gross Profit 5 625,000 48 000,000 216 000,000
Expenses
• Sales & Marketing 5 062,500 38 400,000 151 200,000 70%
• Customer Service 1 687,500 9 600,000 21 600,000 10%

• Product
Development 562,500 2 400,000 10 800,000 5%
• Research 281,250 2 400,000 4 320,000 2%
Total Expenses 7 593,750 52 800,000 187 920,000
Contoso
EBIT -1 968,750 -4 800,000 28 080,000 13% Pharmaceuticals

page 30
Team

Mirjam Nils Victoria Lindqvist Angelica Astrom

COO COB CFO

Lorem ipsum dolor sit amet,
consectetur adipiscing elit. Etiam
aliquet eu mi quis lacinia. Ut
fermentum a magna ut eleifend.
Integer convallis suscipit ante eu
varius.
Morbi a purus dolor. Suspendisse sit
amet ipsum finibus justo viverra
blandit. Ut congue quis tortor eget
sodales. Nulla a erat eget nunc
hendrerit ultrices eu nec nulla.
Donec viverra leo aliquet, auctor quam
id, convallis orci. Sed in molestie est.
Cras ornare turpis at ligula posuere, sit
amet accumsan neque lobortis.

Contoso
Pharmaceuticals

page 31
Team Alternate

Mirjam Victoria Alexander

Nilsson Lindqvist Martensson
COO COB CFO

Angelica Mira Flora

Astrom Karlsson Berggren
Head of Operations Head of Technical Creative Director

Contoso
Pharmaceuticals

page 32
Funding

Fund Category Fund Category

Etiam aliquet eu mi quis lacinia.
Lorem ipsum dolor sit amet,
Ut fermentum a magna ut.
consectetur adipiscing elit.
$12,000
$14,000

$32,000

$82,000

Fund Category Fund Category

. Integer convallis suscipit ante eu Suspendisse sit amet ipsum finibus
varius. Morbi a purus dolor. justo viverra blandit. Ut congue quis
tortor eget sodales. Contoso
Pharmaceuticals

page 33
Thank You
April Hansson

+1 23 987 6554
april@contoso.com
Contoso
www.contoso.com Pharmaceuticals

page 34
Customize this Template

Template Editing
Instructions and Feedback

Contoso
Pharmaceuticals

page 35